CF
ADCT icon

CNA Financial’s ADC Therapeutics ADCT Stock Holding History

CNA Financial’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,945
Closed -$67K – 78
2022
Q3 		$67K Sell
13,945
-1,570
-10% -$11.4K 0.03% 166
2022
Q2 		$123K Hold
15,515
– – 0.04% 170
2022
Q1 		$228K Buy
15,515
+270
+2% +$4.29K 0.07% 178
2021
Q4 		$308K Buy
15,245
+440
+3% +$10.6K 0.08% 179
2021
Q3 		$402K Sell
14,805
-2,220
-13% -$56.9K 0.11% 174
2021
Q2 		$415K Buy
17,025
+1,339
+9% +$31.1K 0.12% 177
2021
Q1 		$383K Buy
15,686
+4,911
+46% +$142K 0.12% 171
2020
Q4 		$345K Buy
10,775
+3,690
+52% +$121K 0.11% 179
2020
Q3 		$234K Buy
7,085
+2,220
+46% +$96.1K 0.09% 177
2020
Q2 		$228K Buy
+4,865
New +$185K 0.09% 171

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CNA Financial's ADCT Position: Q4 2022 in Review

CNA Financial sold out of ADC Therapeutics (ADCT) in Q4 2022, closing a stake of 13,945 shares — an estimated $67K sold.

CNA Financial first reported a position in ADCT in Q2 2020 and held it in 10 quarters. The position peaked at $415K in Q2 2021. 60 funds tracked by Wall St. Rank hold ADCT as of Q4 2022.

  • CNA Financial reported no remaining ADC Therapeutics position as of Q4 2022 after selling out during the quarter.
  • CNA Financial sold 13,945 ADC Therapeutics shares in Q4 2022, an estimated $67K.
  • CNA Financial first reported a position in ADC Therapeutics in Q2 2020 and held it in 10 quarters.
  • CNA Financial's ADC Therapeutics position peaked at $415K in Q2 2021.
  • 60 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2022.

Based on CNA Financial's 13F filing for Q4 2022, filed 10 Feb 2023.